Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Feb;100(2):e63-7.
doi: 10.3324/haematol.2014.112557. Epub 2014 Nov 25.

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

Kevin W Song  1 , Meletios A Dimopoulos  2 , Katja C Weisel  3 , Philippe Moreau  4 , Antonio Palumbo  5 , Andrew Belch  6 , Stephen Schey  7 , Pieter Sonneveld  8 , Lars Sternas  9 , Xin Yu  9 , Ramesh Amatya  10 , Mara S Monzini  9 , Mohamed Zaki  9 , Christian Jacques  9 , Jesus San Miguel  11
Affiliations
Randomized Controlled Trial

Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma

Kevin W Song et al. Haematologica. 2015 Feb.
No abstract available

Keywords: Pomalidomide; multiple myeloma; quality of life.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trial design. aProgression of disease was independently adjudicated in real time. bHiDEX was chosen as comparator because at the time of trial design it was the standard salvage therapy for heavily pre-treated patients. D: days; HiDEX: high-dose dexamethasone; LoDEX: low-dose dexamethasone; OS: overall survival; PD: progressive disease; POM: pomalidomide; SPM: second primary malignancy.
Figure 2.
Figure 2.
Cross-sectional analysis of mean HRQoL score changes from baseline per treatment cycle. *P<0.05 unpaired t-test comparing the two treatment groups from baseline; ‡P<0.05 paired t-test (within group mean change from baseline).
Figure 3.
Figure 3.
Repeated measure mixed model score changes from baseline (adjusted means). P values indicate unpaired t-test comparing treatment groups. *Significant P value (P<0.05).
See this image and copyright information in PMC

References

    1. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–157. - PMC - PubMed
    1. Boland E, Eiser C, Ezaydi Y, Greenfield DM, Ahmedzai SH, Snowden JA. Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. J Pain Symptom Manage. 2013; 46(5):671–680. - PubMed
    1. Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psychooncology. 2011;20(1):88–97. - PubMed
    1. Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–1066. - PubMed
    1. Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol. 2011;87(4):330–337. - PubMed

MeSH terms

Associated data